Purpose: The transcription factor Sp1 controls number of cellular processes by regulating the expression of critical cell cycle, differentiation and apoptosis-related genes containing proximal GC/GT-rich promoter elements. We here provide both experimental and clinical evidence that Sp1 plays an important regulatory role in MM cell growth and survival.
Significant biological role of Sp1 transactivation in multiple myeloma
Mariateresa Fulciniti 1, 2 , Samir Amin Sp1 regulates gene expression both by direct interaction with promoter elements as well as via protein-protein interactions or interplay with other transcription factors, such as Ets-1, cmyc, c-Jun, Stat1, and Egr-1, and/or components of the basal transcriptional machinery (2) . Sp1 has been also linked to chromatin remodeling through interactions with chromatin-modifying factors such as p300 (3) and histone deacetylases (HDACs) (4) .
Although Sp1 has been considered as a ubiquitous transcription factor, increasing evidence suggests that it plays a major role in regulating expression of cell differentiation, cell cycle and apoptosis related genes affecting cellular growth (5) . Sp1 levels and/or activity are increased in multiple cancers including breast (6) , colon (7) , gastric (8) , pancreatic (9) (10) (11) (12) , and thyroid cancer (13) as compared with normal tissues. Elevated Sp1 expression is inversely correlated with the survival of patients with gastric cancer (14) and identifies advanced stage tumors and predicts a poor clinical outcome in primary pancreatic adenocarcinoma (12) . On the other hand, interference of Sp1 activity has been shown to suppress tumor cell growth (15, 16) as well as tumor formation in athymic mice (6, 17) suggesting that Sp1 plays a central regulatory role in controlling number of pathways of tumor development and progression and thus may be an attractive therapeutic target.
Sp1 could contribute to transformation via regulation of the expression of Sp1-responsive genes including those supporting cell growth (c-jun, Raf, cyclins, E2F1, TGF-β, IEX-1 and TCL1) (18, 19) and apoptosis (Bcl-2, Survivin) (5, 20) . Sp1 also regulates genes involved in angiogenesis and metastasis, including VEGF, uPA (21) , PSA, and MT1-MMP (22) . Enhanced Sp1 activity is related to both increased Sp1 gene expression and its posttranslational modification; for example, Sp1 phosphorylation regulates target genes in both positive and negative directions (23, 24) . Although Sp1 has been described to modulate autocrine IL-6 secretion by MM cells affecting its growth (25) , its role in MM pathobiology remains unexplored. The promoter of several genes such as NF-kB p65, IGF-IR, VEGF, hTERT and IL-6 that regulate MM cell growth, cell cycle progression, survival and apoptosis contains proximal GC-rich promoter were transiently transfected with 1 µg of Sp1 reporter plasmid or empty vector control by electroporation using AMAXA technology according to the manufacturer's instructions.
Luciferase assays were performed with a Luminoskan Ascent 2.4 luminometer and the DualLuciferase Reporter Assay System (Promega). Firefly luciferase values were normalized to Renilla luciferase activity and were either expressed as relative luciferase units (RLU) or as mean 'fold induction'.
Sp1 knock down:
siRNA. RNA interference was performed using the TranSilent Human Sp1 siRNA (Panomics, Inc., Redwood, CA) following the manufacturer's instructions. Nontargeting scrambled negative control siRNA (Panomics, Inc., Redwood, CA) was used as negative control. Briefly, U266 and OPM2 cells were seeded to 80% confluence in six-well plates in triplicate and transiently transfected with 2 µM of Sp1 siRNA by electroporation using AMAXA technology.
shRNA. Lentiviral shRNA were used to knockdown Sp1 expression in MM cells. Scrambled and Sp1 pLKO shRNA vectors were provided by Dr. William Hahn (Dana-Farber Cancer Institute).
Recombinant lentivirus was produced by transient infection of 293T cells following a standard protocol, as previously described (31) .
Immunoblotting. Whole cell lysates, nuclear extracts or cytsolic fractions of lysates (30 µg) were subjected to SDS-PAGE using "Precast Gel" (Bio-Rad Laboratores, Melville, NY), transferred to a nitrocellulose membrane (Bio-Rad), and immunoblotted with anti -Sp1 (Abcam) -Survivin, -Caspase-3,-7,-8,-9, -PARP (Cell Signaling Technology, Danvers, MA) antibodies (Abs). After incubating with secondary Ab, membranes were developed by enhanced chemiluminescence (GE Healthcare, Piscataway, NJ).
In vivo study:
s.c. model. The in vivo efficacy of TMP was tested in a murine xenograft model of MM using U266, MM1S or OPM2 MM cell lines injected s.c. in SCID mice. Following detection of tumor, mice were treated with either vehicle or TMP (50 mg/Kg) s.c. for 5 consecutive days/week for 2 weeks. Tumor growth was measured as previously described (32). Excised tumors from mice were immediately fixed and stored in 10% formalin. The fixed tissue was then dehydrated through a series of graded alcohols and xylene and embedded in paraffin. The paraffin tissue blocks were thin sectioned and stained for microscopy with H&E or analyzed by immunocytochemical methods for Ki67, tunel and caspase-3. The survivin level analysis was Statistical analysis. The statistical significance of differences was analyzed using the t test; differences were considered significant when P≤ 0.05. Tumor growth inhibition and KaplanMeier survival analysis were determined using the Graphpad analysis software.
Research. 
Results
High Sp1 protein expression and activity in MM. Sp1 is ubiquitously expressed in cells; however, its nuclear localization is important for functional activity. We first evaluated nuclear Sp1 protein levels in MM cell lines and normal PBMC. All MM cell lines had high nuclear Sp1 expression while normal PBMCs had predominantly cytoplasmic Sp1 with relatively small amount of nuclear localization (Fig. 1A-B) . We further confirmed increased Sp1 nuclear levels and binding activity in MM cells compared to PBMC and BMSC using an ELISA-based Sp1 binding assay (Fig. 1C) .
As activation of Akt and Erk signaling pathways induces nuclear translocation and activation of Sp1 (21) and these pathways are activated in MM cells by their interaction with BM microenvironment, we investigated whether the presence of BMSC could modulate Sp1 activity in MM cells. Using a plasmid containing renilla luciferase reporter gene driven by Sp1-responsive promoter, we observed that the interaction between MM cells and BMSC significantly induced the transcriptional activity of Sp1 in MM cells (Fig. 1D ). This increase was completely abrogated by the ERK pathway inhibitor U0126 but not by the AKT inhibitor LY29004. Fig. 2A-B) . Interestingly, we also found that reduction of Sp1 levels was associated with inhibition of MM cell proliferation ( Fig. 2C ) and significant changes in the cell cycle with increase in G2/M and decrease in S phases (Fig. 2D) . We have confirmed these data using OPM2 cells (Fig. 2E ). Additionally, using 5 different Sp1-specific shRNA constructs, we have confirmed the inhibitory effect of Sp1 knockdown on MM1S cell proliferation and Sp1 activity (Fig. 2F) . The cell populations with the largest reduction in Sp1 protein (shRNA #2, #3, #5) showed the greatest cell growth inhibition, compared to the vector control cell lines. Two of the Sp1 shRNAs that do not efficiently knock down Sp1 has less or no effect on phenotype, indirectly but reliably confirming the specificity of the effect. We used Following exposure to TMP, we have also observed increase in G2/M and decrease in S phases of the cell cycle (Fig. 4A) , as well as late induction of apoptotic cell death (Fig. 4B ) in MM cells. We have further observed activation of the mitochondrial apoptotic pathway by TMP via activation of caspase-9, -3 and -7 and PARP cleavage while caspase-8 was not activated (Fig.   4C ). Change in the protein expression of survivin, a known anti-apoptotic gene transcriptionally regulated by Sp1 (37), was confirmed following TMP treatment (Fig. 4C) . Since caspase activation is a relatively late event, the reduction in survivin protein level during TMP-induced apoptosis appears to be an early event not mediated by caspase-dependent pathway. We have 
TMP as measured by shuIL-6R levels in murine blood, suggesting MM cell growth inhibitory effects of TMP (Fig. 5E ).
Discussion
Alteration in expression and function of transcription factors has been frequently associated with neoplastic transformation. In this study, we provide experimental evidence that Sp1, a transcription factor that controls number of cellular processes, plays an important regulatory role in MM cell growth and survival.
Although Sp1 is ubiquitously expressed, its nuclear localization, observed in MM is functionally important. We have confirmed high Sp1 activity in MM cells both by demonstrating increased DNA binding as well as increased Sp1-responsive promoter activity measured by luciferase reporter assay. We here further confirmed effect of Sp1 on MM cell growth by using both SiRNA and ShRNA-mediated Sp1 knock-down using multiple constructs. Having defined the cellular, signaling and the molecular mechanisms of sensitivity of MM to TMP, rationally designed combinations of conventional and novel agents to enhance cytotoxicity, to avoid or overcome drug resistance and to minimize adverse side effect profiles could be developed. More recently, it has been reported that both lenalidomide and pomalidomide upregulate Sp1 providing a rationale for their preclinical evaluation to increase cytotoxicity and overcome drug resistance (50).
In conclusion, we report significant role of Sp1 in myeloma cell growth and survival with its influence on clinical outcome in MM. Our preclinical in vitro and in vivo results suggest that specific inhibition of Sp1 activity may be an interesting potential therapeutic target alone and in combination with other agents in MM.
